Daré Bioscience (NASDAQ:DARE) Shares Scheduled to Reverse Split on Monday, July 1st

Daré Bioscience, Inc. (NASDAQ:DARE) shares are going to reverse split before the market opens on Monday, July 1st. The 1-12 reverse split was announced on Monday, July 1st. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, July 1st.

Daré Bioscience Price Performance

NASDAQ DARE traded down $0.06 on Thursday, reaching $0.37. The company had a trading volume of 3,250,491 shares, compared to its average volume of 574,012. The firm has a market capitalization of $37.25 million, a PE ratio of -1.15 and a beta of 1.35. Daré Bioscience has a 1 year low of $0.27 and a 1 year high of $0.95. The firm has a 50-day moving average of $0.39 and a 200-day moving average of $0.40.

Daré Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.52 million. During the same period in the previous year, the company posted ($0.09) EPS. As a group, sell-side analysts expect that Daré Bioscience will post -0.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Daré Bioscience in a research report on Wednesday, May 15th. Brookline Capital Management raised Daré Bioscience from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Wednesday, May 15th.

Institutional Investors Weigh In On Daré Bioscience

A hedge fund recently bought a new stake in Daré Bioscience stock. Armistice Capital LLC purchased a new stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned approximately 7.37% of Daré Bioscience at the end of the most recent quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.